EVA: Evista Alendronate Comparison

This study has been completed.
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
First received: May 7, 2002
Last updated: July 18, 2006
Last verified: July 2006
The purpose of this study is to determine how treatment with raloxifene compares to treatment with alendronate in postmenopausal women with osteoporosis on the chance of experiencing fractures

Condition Intervention Phase
Drug: raloxifene HCI and alendronate Na
Phase 4

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Eli Lilly and Company:


Ages Eligible for Study:   50 Years to 80 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • 50-80 years of age, inclusive
  • 2 years since last menses
  • Dx femoral neck osteoporosis
  • No vertebral fractures

Exclusion Criteria

  • Poor candidate for study drugs
  • Hx of diseases affecting bone metabolism
  • Hx of breast/estrogen-dependent cancer
  • Current use of osteoporosis drug therapy
  • Hx/high risk of VTE
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00035971

  Show 86 Study Locations
Sponsors and Collaborators
Eli Lilly and Company
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00035971     History of Changes
Other Study ID Numbers: 5548  H3S-US-GGKO 
Study First Received: May 7, 2002
Last Updated: July 18, 2006
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Bone Density Conservation Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on April 27, 2016